Inventor · disambiguated record
Si Tuen Lee-Hoeflich
Also filed as: LEE-HOEFLICH SI TUEN
4 granted patents·7 pending applications·29 citations·filing 2008–2024
72Inventor score
Top patents by PatentIndex Score
11 records- 0194US10385405B2Gene expression markers of tumor resistance to HER2 inhibitor treatmentGENENTECH INC·Filed 2016·Granted Aug 20, 2019·13 cites·16 claims
- 0289US9551033B2Gene expression markers of tumor resistance to HER2 inhibitor treatmentLEE-HOEFLICH SI TUEN·Filed 2010·Granted Jan 24, 2017·15 cites·20 claims
- 0388US12171839B2Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2022·Granted Dec 24, 2024·1 cites·11 claims
- 0479US2025064964A1Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0567US2019323089A1Gene expression markers of tumor resistance to her2 inhibitor treatmentGENENTECH INC·Filed 2019·Application pending·0 cites
- 0657US11357864B2Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2017·Granted Jun 14, 2022·0 cites·23 claims
- 0756US2024294623A1Tgf-beta inhibitors and therapeutic use thereofSCHOLAR ROCK INC·Filed 2022·Application pending·0 cites
- 0854US2025282857A1Tgf-beta inhibitors and use thereofSCHOLAR ROCK INC·Filed 2022·Application pending·0 cites
- 0950US2021228731A1Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1050US2023050148A1Tgf-beta inhibitors and use thereofSCHOLAR ROCK INC·Filed 2021·Application pending·0 cites
- 1144US2010298156A1Gene expression markers of tumor resistance to her2 inhibitor treatmentLEE-HOEFLICH SI TUEN·Filed 2008·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →